Drug Approval | December 03, 2021
Biocon Pharma receives ANDA approval for Mycophenolic acid
This further adds to Biocon’s portfolio of vertically integrated complex drug products
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
The company has has 10 existing labs in India
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The interim data combines three mRNAs into one therapy injected directly into the tumour
Subscribe To Our Newsletter & Stay Updated
